Antiplatelet Agents Based on Cyclooxygenase Inhibition without Ulcerogenesis. Evaluation and Synthesis of 4,5-Bis(4-methoxyphenyl)-2-substituted-thiazoles

Akito Tanaka; Hiroyoshi Sakai; Yukio Motoyama; Takatoshi Ishikawa; Hisashi Takasugi

doi:10.1021/jm00034a017

Antiplatelet Agents Based on Cyclooxygenase Inhibition without Ulcerogenesis. Evaluation and Synthesis of 4,5-Bis(4-methoxyphenyl)-2-substituted-thiazoles

Journal of Medicinal Chemistry ◽

10.1021/jm00034a017 ◽

1994 ◽

Vol 37 (8) ◽

pp. 1189-1199 ◽

Cited By ~ 23

Author(s):

Akito Tanaka ◽

Hiroyoshi Sakai ◽

Yukio Motoyama ◽

Takatoshi Ishikawa ◽

Hisashi Takasugi

Keyword(s):

Antiplatelet Agents ◽

Cyclooxygenase Inhibition

Download Full-text

ChemInform Abstract: Antiplatelet Agents Based on Cyclooxygenase Inhibition Without Ulcerogenesis. Evaluation and Synthesis of 4,5-Bis(4-methoxyphenyl)-2- substituted-thiazoles.

ChemInform ◽

10.1002/chin.199433171 ◽

2010 ◽

Vol 25 (33) ◽

pp. no-no

Author(s):

A. TANAKA ◽

H. SAKAI ◽

Y. MOTOYAMA ◽

T. ISHIKAWA ◽

H. TAKASUGI

Keyword(s):

Antiplatelet Agents ◽

Cyclooxygenase Inhibition

Download Full-text

The present state of aspirin and clopidogrel resistance

Hämostaseologie ◽

10.1055/s-0037-1617036 ◽

2009 ◽

Vol 29 (03) ◽

pp. 285-290 ◽

Cited By ~ 2

Author(s):

K. E. Guyer

Keyword(s):

Diagnostic Tests ◽

Arterial Thrombosis ◽

Cardiovascular Events ◽

Treatment Success ◽

Antiplatelet Agents ◽

Antiplatelet Drug ◽

Coronary Syndrome ◽

Testing Method ◽

Pharmacological Response ◽

Platelet Physiology

SummaryAntiplatelet therapy has demonstrated significant clinical benefit in the treatment of acute coronary syndrome. However, as with any treatment strategy it has been unable to prevent all cardiovascular events. This is far from surprising when considering the complexity of arterial thrombosis and more specifically platelet physiology. This lack of treatment success has provoked the introduction of various diagnostic tests and testing platforms with the intent of guiding and optimizing clinical treatment. Such tests have resulted in the generation of clinical data that suggest suboptimal response to antiplatelet agents such as aspirin and clopidogrel.In the case of both aspirin and clopidogrel, this suboptimal response has been termed resistance. Drug resistance would imply a lack of pharmacological response that has not been specifically investigated in many of the clinical studies performed to date. Rather, the term resistance has been used to describe various facets of platelet activation and aggregation relative to the testing method. Many of these measured parameters are not addressed in the therapeutic intent of the antiplatelet drug in question.

Download Full-text

Anticoagulants of primary haemostasis

Hämostaseologie ◽

10.1055/s-0037-1617031 ◽

2009 ◽

Vol 29 (03) ◽

pp. 274-278 ◽

Cited By ~ 1

Author(s):

U. Steigerwald ◽

U. Walter ◽

J. Kössler

Keyword(s):

Experimental Studies ◽

Antiplatelet Agents ◽

Bleeding Risk ◽

Factor Xii ◽

Receptor Antagonists ◽

Thromboxane Receptor ◽

Adenosine Uptake ◽

Interaction Factor ◽

Favorable Clinical Outcome ◽

Adp Receptor Antagonists

SummaryInhibition of platelet function plays an important role in the treatment and secondary prevention of cardiovascular or cerebrovascular ischemic diseases. Established antiplatelet agents use different pharmacological targets for this role. Acetylic salicylic acid achieves a reduction of thromboxane A2 formation by inhibition of COX-1. Ticlopidin or clopidogrel are ADP-P2Y12 receptor antagonists. Tirofiban, abciximab or eptifibatid are used for the inhibition of the glycoprotein IIb/IIIa receptor which is activated at the surface of platelets preceding the final step of their aggregation. The mechanism of dipyridamole is based on the inhibition of adenosine uptake and of phosphodiesterase-5.Efforts are made to improve antiplatetelet therapy with the aim to find agents with favorable clinical outcome and lower bleeding risk. Current clinical studies focus on a new generation of ADP receptor antagonists (prasugrel, cangrelor and ticagrelor) as successors of ticlopidin and clopidogrel after coronary arterial interventions. Developments using platelet targets different from established drugs are thrombin receptor antagonists (like SCH530348) or thromboxane receptor antagonists (like S18886/terutroban) in patients with cerebrovascular events. Results from recent experimental studies could lead to new strategies for antiplatetelet therapy (like inhibition of GP Ib receptor, GP VI receptor, platelet-leukocyte interaction, factor XII and others) in the future.

Download Full-text